Debiopharm Research & Manufacturing S.A., a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services , a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink technology for preclinical services.
Health Technology Insights: TeleVox Unveils End-to-End Call Analytics Solution Insights360
AbYlink is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
Health Technology Insights: Meridian Bioscience Launches Enzyme Stabilization for Diagnostics
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
Health Technology Insights: MammoScreen Breast AI Adopted by Mayo Clinic for Radiology Use
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
